Compare ELOX & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELOX | NEPH |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | United States |
| Employees | 7 | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.8M | 40.1M |
| IPO Year | N/A | 2004 |
| Metric | ELOX | NEPH |
|---|---|---|
| Price | $11.66 | $3.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 48.2K | 8.4K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1000.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $18,789,000.00 |
| Revenue This Year | N/A | $11.24 |
| Revenue Next Year | N/A | $11.58 |
| P/E Ratio | ★ N/A | $350.00 |
| Revenue Growth | N/A | ★ 32.67 |
| 52 Week Low | $10.00 | $2.66 |
| 52 Week High | $15.00 | $6.42 |
| Indicator | ELOX | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 38.06 | 56.24 |
| Support Level | N/A | $2.77 |
| Resistance Level | $15.00 | $3.78 |
| Average True Range (ATR) | 2.29 | 0.25 |
| MACD | -0.09 | 0.02 |
| Stochastic Oscillator | 27.50 | 73.33 |
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.